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Comment

Assessing the necessity of chimpanzee
experimentation
On December 15, 2011, the US Institute of Medicine (IOM)
released Chimpanzees in Biomedical and Behavioral Research:
Assessing the Necessity (Altevogt et al., 2011a). The report responded to a National Institutes of Health (NIH) request for expert guidance on the scientific need to use chimpanzees within
such research.
The IOM committee concluded that most current use of
chimpanzees for biomedical research – including RSV vaccine,
therapeutic hepatitis C (HCV) vaccine, and HCV antiviral drug
development – is not warranted, with the possible exception
of two very limited research uses: for the production of monoclonal antibodies (mAbs) and the development of prophylactic
HCV vaccines. The committee stated, “it will be very difficult to
defend the necessity of nearly all current biomedical research
on chimpanzees.” Yet it stopped short of recommending an outright ban (Altevogt et al., 2011b).
Even this limited support of invasive chimpanzee research is
questionable, however. The committee noted that, “Production
of monoclonal antibodies after immunization in other species
or through in vitro synthetic methods is equally powerful for
the generation of such reagents.” They also noted four methods
currently in use that lessen the need for safety tests of mAbs in
chimpanzees. However, they still supported the use of chimpanzees for mAbs developed using older technologies, although
they expected such use would cease within five years. Yet, it
would seem far more ethical, and could also potentially yield
safety, efficacy and financial benefits, if the most modern technologies were used without further delay. As Bettauer (2011)
noted with respect to chimpanzee use in mAb research and drug
development, “Available alternatives, together with ethical and
economic reasons, suggest that the use of the chimpanzee in this
manner may not be necessary or appropriate.”
The committee noted that HCV antiviral drug and therapeutic
vaccine development does not require the use of chimpanzees,
but were uncertain about their necessity for the development of
prophylactic vaccines. However, they also noted the existence
of alternative research strategies: “studies in consenting individuals at high risk for natural HCV infection can be ethically
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done provided that these vaccines are first shown to be safe and
immunogenic in experimental animals, such as mice and nonhuman primates.” After reviewing 109 chimpanzee HCV studies,
Bettauer (2010) found considerable problems with statistical
validity, repeatability, and the biological relevance of the chimpanzee model. Bailey (2010) similarly found that, “claims of
the necessity of chimpanzees in historical and future hepatitis
C research are exaggerated and unjustifiable, respectively.” He
concluded that, “Unfounded claims of its necessity should not
discourage changes in public policy regarding the use of chimpanzees in US laboratories.”
Although the committee failed to identify any current biomedical research field in which invasive chimpanzee studies
are definitely necessary, it concluded that, “a new, emerging,
or reemerging disease or disorder may present challenges to
treatment, prevention, and/or control that defy non-chimpanzee
models and technologies and thus may require their future use.
Therefore, an outright ban on biomedical chimpanzee research
would not be appropriate.”
In reaching this conclusion, however, the committee made
very little mention of the profound animal welfare and ethical problems raised by invasive chimpanzee research. The
advanced cognitive, sociological and related characteristics of
chimpanzees render their use particularly ethically problematic. Such research is also particularly costly. Accordingly, the
concrete benefits of such research – particularly in advancing
human healthcare – must be particularly substantial, probable
and independently verifiable, in order for it to be considered
ethically and fiscally justifiable. Yet the relevant systematic reviews published to date suggest that this is far from the case.
The contributions of invasive chimpanzee research to biomedical progress appear highly questionable, and it rarely, if ever,
makes important contributions to clinical interventions efficacious in human patients (Bailey, 2008, 2009, 2010; Bettauer,
2010, 2011; Knight, 2007, 2008).
This is why almost all nations that have considered invasive
chimpanzee experimentation have implemented policy or legislative bans on such research, with the exception of noninvasive
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observational or behavioral research, or research conducted at
ensuring the survival of the individual in question, or of the species. Only the US, and possibly Gabon – whose status is unclear
– still persist with invasive chimpanzee research.
The US should utilize the opportunity afforded by the Great
Ape Protection and Cost Savings Act of 2011 to similarly ban
invasive chimpanzee experimentation. This would not require
the banning of all chimpanzee research, however. Clear-cut examples include non-invasive observational or behavioral studies
of free-living or sanctuary chimpanzees, and experimental treatment of chimpanzees genuinely suffering from severe, naturally
occurring disease or injury, when conventional treatment is
ineffective. Rigorous implementation of policies such as these
would restore to chimpanzee research the balance between human and animal interests expected by society, and demanded by
detailed ethical review.
Instead however, the committee concluded that invasive
chimpanzee research would be acceptable if it met certain criteria: the knowledge gained must be necessary to advance public
health; the research cannot ethically be conducted on a human
being, and is impossible using other species or inanimate research tools; and the chimpanzees used must be maintained in
natural habitats or in physical and social environments that are
similarly ethologically appropriate. Additionally, forgoing the
use of chimpanzees for the research in question must significantly slow or prevent important advancements to prevent, control, and/or treat life-threatening or debilitating conditions. For
studies of comparative genomics and behavioral research, the
criteria were that studies must provide otherwise unobtainable
insights into comparative genomics, normal and abnormal behavior, mental health, emotion, or cognition; and that all experiments must be performed on acquiescent animals (who participate voluntarily, without coercion), using techniques that are, at
most, minimally invasive, painful or distressing.
NIH Director Francis Collins accepted the committee’s recommendations. The NIH announced that until it issues further
policy implementing these recommendations, it will not fund
any new or competing projects (that is, renewals and revisions) involving chimpanzee research; nor will it allow any new
projects to proceed using NIH owned or supported chimpanzees
(NIH, 2011). A project-by-project review will also be conducted
to determine whether ongoing research fits the recommended
criteria. Dr Collins estimated that about 37 research projects
might be affected, of which perhaps half could be discontinued
(Anon., 2011; Collins, 2011).
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